Financial Comparison: Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) versus Acura Pharmaceuticals (ACUR)

Acura Pharmaceuticals (OTCMKTS: ACUR) and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Volatility & Risk

Acura Pharmaceuticals has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Acura Pharmaceuticals and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acura Pharmaceuticals 0 0 0 0 N/A
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share 0 0 2 0 3.00

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a consensus price target of $25.00, indicating a potential upside of 188.35%. Given Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s higher probable upside, analysts plainly believe Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share is more favorable than Acura Pharmaceuticals.

Insider and Institutional Ownership

9.4% of Acura Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share shares are owned by institutional investors. 5.6% of Acura Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Acura Pharmaceuticals and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acura Pharmaceuticals -36.20% -231.18% -31.56%
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share 44.47% 33.92% 8.94%

Valuation and Earnings

This table compares Acura Pharmaceuticals and Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acura Pharmaceuticals $4.46 million 1.77 -$7.38 million ($0.14) -2.71
Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share $150.25 million 2.31 -$41.27 million $1.90 4.56

Acura Pharmaceuticals has higher earnings, but lower revenue than Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share. Acura Pharmaceuticals is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Summary

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share beats Acura Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Acura Pharmaceuticals Company Profile

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply